A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 2/3 Clinical Trial to Evaluate the Safety and Efficacy of Pyronaridine-artesunate (Artecom) in COVID-19 Patients
Latest Information Update: 08 Sep 2023
At a glance
- Drugs Artesunate/pyronaridine (Primary)
- Indications COVID-19 respiratory infection
- Focus Registrational; Therapeutic Use
- Acronyms PROVIDENCE
- Sponsors Shin Poong Pharmaceutical
- 28 Sep 2021 Planned End Date changed from 15 Oct 2021 to 15 Apr 2022.
- 28 Sep 2021 Planned primary completion date changed from 15 Oct 2021 to 15 Apr 2022.
- 28 Mar 2021 Planned End Date changed from 30 Sep 2021 to 15 Oct 2021.